#direct-acting antivirals

Researchers conducted an analysis of hep C treatment outcomes in those also living with HIV in Western nations.

Large European study finds that more than 1 in 10 people with HIV acquire HCV again.

Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.

In fact, antiviral drugs account for nearly 14 percent of total drug costs in the program.

Those with greater fibrosis before treating hep C see the greatest benefit.

Research found that healthcare providers could do better at preventing drug interactions.

People who have a low CD4 count, have cirrhosis and take certain hep C drug regimens are less likely to be cured.

Human rights activist Philip Baldwin writes about his experiences living with hepatitis C and HIV, and his treatment for hep C.

Mavyret taken for eight weeks was well tolerated and cured all HIV-positive people without cirrhosis in a recent study

Battle lines are drawn as the global health community prepares to face off with Big Pharma over the astronomic cost of treatment.

An international Hep C activist group is calling on government regulators and pharmaceutical companies developing therapies for HCV...